JP2020527547A5 - - Google Patents

Download PDF

Info

Publication number
JP2020527547A5
JP2020527547A5 JP2019572783A JP2019572783A JP2020527547A5 JP 2020527547 A5 JP2020527547 A5 JP 2020527547A5 JP 2019572783 A JP2019572783 A JP 2019572783A JP 2019572783 A JP2019572783 A JP 2019572783A JP 2020527547 A5 JP2020527547 A5 JP 2020527547A5
Authority
JP
Japan
Prior art keywords
compound according
liver
formula
subject
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019572783A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527547A (ja
JP7374000B2 (ja
Filing date
Publication date
Priority claimed from GBGB1710229.4A external-priority patent/GB201710229D0/en
Application filed filed Critical
Publication of JP2020527547A publication Critical patent/JP2020527547A/ja
Publication of JP2020527547A5 publication Critical patent/JP2020527547A5/ja
Priority to JP2023107837A priority Critical patent/JP7632979B2/ja
Application granted granted Critical
Publication of JP7374000B2 publication Critical patent/JP7374000B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019572783A 2017-06-27 2018-06-22 肝臓脂肪を減らすことにおいて使用するための3-ヒドロキシ酪酸化合物 Active JP7374000B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023107837A JP7632979B2 (ja) 2017-06-27 2023-06-30 肝臓脂肪を減らすことにおいて使用するための3-ヒドロキシ酪酸化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1710229.4 2017-06-27
GBGB1710229.4A GB201710229D0 (en) 2017-06-27 2017-06-27 Compounds for new use
PCT/GB2018/051752 WO2019002828A1 (en) 2017-06-27 2018-06-22 3-HYDROXYBUTYRATE COMPOUNDS FOR USE IN THE REDUCTION OF HEPATIC FAT

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023107837A Division JP7632979B2 (ja) 2017-06-27 2023-06-30 肝臓脂肪を減らすことにおいて使用するための3-ヒドロキシ酪酸化合物

Publications (3)

Publication Number Publication Date
JP2020527547A JP2020527547A (ja) 2020-09-10
JP2020527547A5 true JP2020527547A5 (enExample) 2021-07-29
JP7374000B2 JP7374000B2 (ja) 2023-11-06

Family

ID=59523693

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019572783A Active JP7374000B2 (ja) 2017-06-27 2018-06-22 肝臓脂肪を減らすことにおいて使用するための3-ヒドロキシ酪酸化合物
JP2023107837A Active JP7632979B2 (ja) 2017-06-27 2023-06-30 肝臓脂肪を減らすことにおいて使用するための3-ヒドロキシ酪酸化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023107837A Active JP7632979B2 (ja) 2017-06-27 2023-06-30 肝臓脂肪を減らすことにおいて使用するための3-ヒドロキシ酪酸化合物

Country Status (13)

Country Link
US (2) US12439944B2 (enExample)
EP (2) EP4215189A1 (enExample)
JP (2) JP7374000B2 (enExample)
KR (1) KR102680437B1 (enExample)
CN (1) CN110869012B (enExample)
AU (1) AU2018293398B2 (enExample)
CA (1) CA3066948A1 (enExample)
DK (1) DK3644982T3 (enExample)
ES (1) ES2945964T3 (enExample)
GB (2) GB201710229D0 (enExample)
PL (1) PL3644982T3 (enExample)
TW (1) TWI811222B (enExample)
WO (1) WO2019002828A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201710229D0 (en) 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use
GB201715654D0 (en) * 2017-09-27 2017-11-08 Tdeltas Ltd Method of treatment
GB2577723A (en) 2018-10-04 2020-04-08 Tdeltas Ltd Compounds for new use
US12258609B2 (en) 2019-01-17 2025-03-25 Ketolipix Therapeutics Gmbh Method for producing glycerides of hydroxycarboxylic acids
CN109700021A (zh) * 2019-03-04 2019-05-03 清华大学 3-羟基丁酸及其衍生物在制备预防和治疗肥胖及肥胖相关疾病的产品中的应用
CN110776425B (zh) * 2019-10-23 2021-02-26 清华大学 一种(r)-3-羟基丁酸及其低聚物的制备方法
JP7638693B2 (ja) * 2020-12-15 2025-03-04 大阪瓦斯株式会社 ヒドロキシアルカン酸結晶の製造方法及びヒドロキシアルカン酸の結晶多形体
WO2022254764A1 (ja) * 2021-06-01 2022-12-08 大阪瓦斯株式会社 3-ヒドロキシ酪酸含有油脂組成物
WO2023283654A1 (en) * 2021-07-09 2023-01-12 Georgia State University Research Foundation, Inc. The use of beta-hydroxybutyrates for the treatment or prevention of aneurysms and dissections
IT202100020441A1 (it) * 2021-07-30 2023-01-30 Unichem Estense S R L Miscela di un mono-estere e un di-estere, in cui detti mono-estere e di-estere sono esteri dell’acido (R)-3-idrossibutanoico con un polialcol, processo per la preparazione della miscela e relativi usi medici
CN113712140A (zh) * 2021-09-13 2021-11-30 珠海麦得发生物科技股份有限公司 一种含(r)-3羟基丁酸的固体饮料及其制备方法
AU2022381752B2 (en) * 2021-11-04 2026-01-08 Vdf Futureceuticals, Inc Ketone precursors and methods therefor
AU2022387742A1 (en) * 2021-11-12 2024-06-27 Arxada Ag Polyol-derived compounds
CN118382365A (zh) * 2021-12-14 2024-07-23 三得利控股株式会社 含有3羟基丁酸及低级脂肪族醇的饮料及呈味改善方法
CN118541034A (zh) * 2021-12-14 2024-08-23 三得利控股株式会社 碳酸饮料及增强碳酸饮料的碳酸感的方法
JP7223193B1 (ja) 2022-05-26 2023-02-15 大阪瓦斯株式会社 内臓脂肪低減剤およびその用途
CN116966173A (zh) * 2023-06-15 2023-10-31 浙江大学 3-羟基苯乙酸在制备改善非酒精性脂肪肝药物中的应用
CN118903420A (zh) * 2024-07-02 2024-11-08 南方医科大学 Irf4抑制剂在治疗非酒精性脂肪性肝炎的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1248321B (it) * 1991-05-15 1995-01-05 Sigma Tau Ind Farmaceuti Uso di esteri di acil l-carnitine con l'acido gamma-idrossibutirrico per produrre composizioni farmaceutiche per il trattamento di epatopatie
AU6513298A (en) 1997-03-17 1998-10-12 British Technology Group Limited Therapeutic compositions
US6323237B1 (en) 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
US20090253781A1 (en) 2002-05-24 2009-10-08 Btg International Limited Therapeutic compositions
ATE345359T1 (de) * 1997-12-22 2006-12-15 Metabolix Inc Polyhydroxyalkanoatzusammensetzungen mit kontrollierten abbaugeschwindigkeiten
US6753384B2 (en) * 2000-07-14 2004-06-22 Metabolix, Inc. Polyurethanes obtained from hydroxyalkanoates and isocyanates
AU2004245567B2 (en) 2003-06-03 2011-06-23 Oxford University Innovation Limited Nutritional supplements and therapeutic compositions comprising (R)-3-hydroxybutyrate derivatives
SE0400355D0 (sv) * 2004-02-17 2004-02-17 Synbiotics Ab New synbiotec use
EP1778213B1 (en) 2004-07-16 2017-04-05 BTG International Limited A method for the synthesis of oligomeric compounds
US7485743B2 (en) 2004-07-20 2009-02-03 Btg International Limited Oligomeric ketone compounds
WO2008110034A1 (en) * 2007-03-14 2008-09-18 Shantou University 3-hydroxy fatty acid and its derivatives for improving of learning and/or memory of subjects
ES2730879T3 (es) 2008-01-04 2019-11-13 Univ Oxford Innovation Ltd Cuerpos de cetona y ésteres de cuerpos de cetona como agentes reductores de lípidos de la sangre
ES2655367T3 (es) * 2008-08-21 2018-02-19 Oxford University Innovation Limited Bebida que comprende éster de hidroxibutirato y uso médico de la misma
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
WO2011078204A1 (ja) 2009-12-24 2011-06-30 浜理薬品工業株式会社 高脂血症の予防または治療剤、および抗疲労剤
US8865641B2 (en) * 2011-06-16 2014-10-21 The Feinstein Institute For Medical Research Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways
GB201206192D0 (en) 2012-04-05 2012-05-23 Tdeltas Ltd Ketone bodies and ketone body esters and for maintaining or improving muscle power output
CN105246870A (zh) 2013-03-14 2016-01-13 伊希斯创新有限公司 (r)-3-羟基丁酸(r)-3-羟基丁酯的制备方法
PE20151949A1 (es) 2013-03-19 2016-01-05 Univ South Florida Composiciones y metodos para producir cetosis elevada y sostenida
EP2988736A1 (en) 2013-04-22 2016-03-02 Cadila Healthcare Limited A novel composition for nonalcoholic fatty liver disease (nafld)
US11814664B2 (en) * 2013-05-24 2023-11-14 Genomatica, Inc. Microorganisms and methods for producing (3R)-hydroxybutyl (3R)-hydroxybutyrate
GB201314127D0 (en) 2013-08-07 2013-09-18 Tdeltas Ltd Ketone body and ketone body ester for reducing muscle breakdown
US20150283163A1 (en) 2014-04-04 2015-10-08 Organic Medical Ventures, L.L.C. Muscle treatment composition and method making same
WO2016123229A1 (en) * 2015-01-29 2016-08-04 Yale University Compositions and methods for treating nlrp3 inflammasome-related diseases and disorders
MX386778B (es) * 2015-03-09 2025-03-19 Intekrin Therapeutics Inc Métodos para el tratamiento de enfermedad de hígado graso no alcohólico y/o lipodistrofia.
SG11201809211QA (en) * 2016-04-19 2018-11-29 Keto Patent Group Inc Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
GB201710229D0 (en) 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use

Similar Documents

Publication Publication Date Title
JP2020527547A5 (enExample)
US20230293458A1 (en) Multibiotic agents and methods of using the same
Cheng et al. Therapeutic potential of triptolide in autoimmune diseases and strategies to reduce its toxicity
JP7261850B2 (ja) 肝毒性および脂肪性肝疾患の処置に有効な化合物およびその使用
JP5561700B2 (ja) 新規糖脂質及びその用途
US20220409650A1 (en) Compositions and methods for ascaroside modification of mammalian microbiota
JP2011502174A5 (enExample)
CN110183431B (zh) 一类用于肝病治疗或预防的化合物
US20200254105A1 (en) Drug composition for parenteral administration
JP5677951B2 (ja) 抗癌活性を有する2−デオキシ単糖の新規なアセテート
JP6377713B2 (ja) 薬剤
US20090326259A1 (en) NF-Kappabeta Activation Inhibitor
JP6157041B2 (ja) PPARγ活性化剤、抗肥満剤及び抗糖尿病剤
JP2020026434A (ja) 癌治療剤
TW202237073A (zh) 官能化長鏈烴單羧酸及二羧酸及其衍生物以及其於預防或治療疾病之用途
KR20200104352A (ko) 약물의 경구 생체이용률을 향상시키는 방법
JP6043997B2 (ja) 炎症性サイトカインの機能を抑制する炎症性疾患治療剤
WO2023153020A1 (ja) がん細胞増殖抑制剤及びがん細胞増殖抑制効果増強剤
KR102625224B1 (ko) 피라졸-온 유도체를 유효성분으로 포함하는 자가면역질환의 예방, 개선 또는 치료용 조성물
US8614250B2 (en) Uses of adipic acid
JPWO2019234402A5 (enExample)
TWI797455B (zh) 安卓錠化合物用於預防或治療非酒精性脂肪肝病的用途
JP2001226263A (ja) 肥満予防剤
JPWO2020070506A5 (enExample)
WO2025158806A1 (ja) 代謝機能不全に関連した脂肪性肝疾患の予防又は改善剤